Tag Archives: Harbridge

Bayh-Dole re-establishes a patent monopoly pipeline from federal funding to the pharmaceutical industry. The NIH first created this patent pipeline in 1968 when Norman Latker, patent counsel at the NIH, restarted the Institutional Patent Agreement program that had been allowed … Continue reading →